Saudi Arabia's innovative devices pathway moves an AI product to the front of the queue. It does not make the review any shorter, and the entry test can exclude a product already selling abroad.
On 10 September 2026 SFDA granted marketing authorisation to Dental IQ and SAARIA, the first Saudi-developed AI medical software in dentistry and ophthalmology to hold one. Both companies came through the Innovative Medical Devices Pathway. MDS-G002, the guidance that governs it, states that priority review is not shortened or reduced in any way — it commences sooner. What the route actually gives is free pre-submission feedback, a place at the front of the queue and the possibility of a conditional authorisation. What it asks for is a device with no equivalence in the local or global market and a considerable clinical advantage over existing alternatives. For an international AI vendor, that second test is the one that bites.
What a board member needs before the next meeting on this.
- Priority is a queue position, not a faster assessment. MDS-G002 states that priority does not mean the technical file assessment will be shortened or reduced in any way, only that it commences sooner after receipt of the file. A launch plan that books a shorter review has misread the guidance.
- The designation test asks for no equivalence in the local or global market. The criteria are innovative features in technology, indications for use or performance attributes with no equivalence in the local or global market, plus a considerable clinical advantage over existing alternatives. On our reading, a product already competing abroad has a harder case than one that is genuinely first.
- The Saudi clinical study was practice, not rule. SFDA's announcement says both applicants ran local clinical studies in the Kingdom and committed to post-marketing clinical follow-up. MDS-G002 imposes neither as a condition of the pathway. The two approvals show what clearing it looked like, not what the text requires.
- A marketing authorisation here can be conditional. The guidance allows a conditional authorisation with limited distribution and post-market surveillance studies, convertible to full authorisation once all requirements are met. Conditional and full are different assets, and SFDA's announcement does not say which these two are.
The Saudi Food and Drug Authority announced on 10 September 2026 that it had granted marketing authorisation to two locally developed AI-enabled medical software products (SFDA news, 10 September 2026). Dental IQ applies deep learning to dental X-ray images to support identification of caries, periodontal disease and structural change in teeth and supporting tissues. SAARIA analyses retinal fundus images to screen diabetic patients for diabetic retinopathy.
SFDA describes both as the first Saudi-developed AI-enabled medical software in dentistry and ophthalmology to receive its marketing authorisation, and says both companies enrolled in its Innovative Medical Devices Pathway. The approvals are being read as a signal that Saudi Arabia has opened a fast lane for AI diagnostics. The guidance governing that lane says something more precise, and less convenient.
The pathway buys a place in the queue
SFDA sets the route out in MDS-G002, Guidance on Innovative Medical Devices, version 3.0, issued under Article 9 of the Law of Medical Devices promulgated by Royal Decree M/54 of 6/7/1442H (MDS-G002). It has two stages. The first, pre-submission assessment, gives an applicant continuous feedback on its technical file before it applies, free of charge.
The second is priority review of the marketing authorisation application itself. On what priority means the guidance is blunt: it "does not mean that MDMA technical file assessment will be shortened or reduced in any way, it just means that the assessment ... will commence sooner after receipt of the technical file." The wait to start shortens. The review does not.
The entry test is narrower than novelty
A device may be designated innovative if it is "designed with innovative features in the technology, indications for use, or performance attributes that have no equivalence in the local/global market" and "provides a considerable clinical/medical advantage over existing alternative treatments". The applicant carries the burden of justifying both, SFDA may ask for more information, and it notifies the applicant whether the application is accepted for priority review or not.
On our reading of that first criterion, the pathway is aimed at a product that is genuinely first rather than one that is merely new to Saudi Arabia, and a vendor whose AI triage tool already competes against similar products in Europe or the United States has the weaker case. That cuts against the assumption that an existing foreign clearance smooths the way here. It may do the opposite.
Get the instruments that touch your licence, assessed, as they are issued. See Regulatory Watch
Local evidence is what these two did, not what the text demands
SFDA's announcement says the two companies received early regulatory guidance, fulfilled the applicable requirements, conducted local clinical studies in the Kingdom to validate performance in local healthcare settings, and committed to post-marketing clinical follow-up plans to monitor real-world performance. MDS-G002 does not make a Saudi study a condition of the pathway.
The distinction matters when budgeting. The guidance sets the floor; these two approvals show what the floor looked like in practice for AI software read on Saudi patients, and a later applicant that skips local validation is arguing against a precedent rather than against a rule.
Conditional and full are different assets
The guidance allows SFDA to grant a conditional marketing authorisation to an innovative device supported by valid clinical evidence, under post-market requirements that can include limitation of distribution and post-market surveillance studies, with full authorisation available once all requirements are met. SFDA's announcement of the two approvals names neither company, gives no authorisation number and does not say whether either is conditional or full.
For anyone buying, licensing or lending against a Saudi AI-health company, those are not details. A conditional authorisation with distribution limits and an open surveillance obligation is a materially different asset from a full one, and the register entry is the document to ask for rather than the press release.
The contrast with the medicines side is instructive
Saudi Arabia's breakthrough route for medicines has produced a first-in-world registration this year, with review time measured in months from designation. The devices pathway makes no equivalent promise anywhere in its text, and explicitly disclaims one. Anyone planning a GCC regulatory strategy off a single mental model of "Saudi fast track" is carrying a timeline in the device plan that the drug plan earned.
What the precedent actually sets
The useful read of 10 September is not that approval got easier. It is that two Saudi startups established what a complete AI-MD file looks like to this regulator: designation argued and accepted, local clinical evidence generated, post-market follow-up committed. That is now the visible benchmark a reviewer has in front of them. An international entrant that wants the same route must match the shape of it, and one that cannot should plan on the ordinary queue and price the delay rather than discover it.
Four questions before underwriting a Saudi AI device plan
- On what basis would this device satisfy the no-equivalence criterion, and which competing products in the local or global market would SFDA see when it tests that claim?
- If designation is refused, what does the ordinary marketing authorisation queue do to the launch date, and does the commercial plan survive it?
- Is the target's authorisation conditional or full, and if conditional, what distribution limits and post-market surveillance studies attach to it?
- Who owns and funds the post-marketing clinical follow-up commitment, and is it written into the budget and into the sale agreement?
The Monday work is to test the claim before the calendar. Write the no-equivalence argument for the device as SFDA would read it, name the comparator products it has to survive, and decide whether the designation is realistic or whether the plan should assume ordinary review from the start. Where a target already holds an authorisation, obtain the register entry, establish whether it is conditional or full, and read the post-market obligations as a cost and a covenant. That work sits with our market access and regulatory practice.
This brief covers one instrument. The UAE healthcare regulatory tracker carries the full set — DoH, DHA, EDE and the other emirates — with what each one changes and when it takes effect.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.